Absci vs ConcertAI

Side-by-side comparison of AI visibility scores, market position, and capabilities

ConcertAI leads in AI visibility (74 vs 53)
Absci logo

Absci

GrowthBiotechnology

AI Drug Creation

Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up.

AI VisibilityBeta
Overall Score
C53
Category Rank
#50 of 198
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
50
Gemini
53

About

Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means.

Full profile
ConcertAI logo

ConcertAI

LeaderLife Sciences & BioTech

Oncology AI & Real-World Data

ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.

AI VisibilityBeta
Overall Score
B74
Category Rank
#2 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
69
Gemini
70

About

ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.

Full profile

AI Visibility Head-to-Head

53
Overall Score
74
#50
Category Rank
#2
82
AI Consensus
80
stable
Trend
stable
49
ChatGPT
73
50
Perplexity
69
53
Gemini
70
50
Claude
70
56
Grok
77

Key Details

Category
AI Drug Creation
Oncology AI & Real-World Data
Tier
Growth
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Absci
AI Drug Creation

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.